Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary mediastinal B-cell lymphoma.
Johnson PW, Davies AJ. Johnson PW, et al. Among authors: davies aj. Hematology Am Soc Hematol Educ Program. 2008:349-58. doi: 10.1182/asheducation-2008.1.349. Hematology Am Soc Hematol Educ Program. 2008. PMID: 19074109 Review.
III. Applying molecular phenotyping in practice.
Johnson PW, Davies A, Jack A. Johnson PW, et al. Hematol Oncol. 2013 Jun;31 Suppl 1:29-32. doi: 10.1002/hon.2063. Hematol Oncol. 2013. PMID: 23775645 Review. No abstract available.
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Davies A, Cavalli F, Giovanella L, Johnson PW. Martelli M, et al. Among authors: davies a. J Clin Oncol. 2014 Jun 10;32(17):1769-75. doi: 10.1200/JCO.2013.51.7524. Epub 2014 May 5. J Clin Oncol. 2014. PMID: 24799481 Free article. Clinical Trial.
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS. Roghanian A, et al. Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005. Cancer Cell. 2015. PMID: 25873171 Free article.
Obinutuzumab in hematologic malignancies: lessons learned to date.
Illidge T, Klein C, Sehn LH, Davies A, Salles G, Cartron G. Illidge T, et al. Cancer Treat Rev. 2015 Nov;41(9):784-92. doi: 10.1016/j.ctrv.2015.07.003. Epub 2015 Jul 14. Cancer Treat Rev. 2015. PMID: 26190254 Free article. Review.
443 results